- Home
- CAPR vs MEGI Comparison
CAPR vs MEGI Comparison
Compare CAPR & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- MEGI
- Stock Information
- Founded
- CAPR 2005
- MEGI 2021
- Country
- CAPR United States
- MEGI United States
- Employees
- CAPR N/A
- MEGI N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- MEGI Investment Managers
- Sector
- CAPR Health Care
- MEGI Finance
- Exchange
- CAPR Nasdaq
- MEGI Nasdaq
- Market Cap
- CAPR 578.4M
- MEGI 647.0M
- IPO Year
- CAPR N/A
- MEGI N/A
- Fundamental
- Price
- CAPR $15.00
- MEGI $12.65
- Analyst Decision
- CAPR Strong Buy
- MEGI
- Analyst Count
- CAPR 7
- MEGI 0
- Target Price
- CAPR $39.29
- MEGI N/A
- AVG Volume (30 Days)
- CAPR 902.1K
- MEGI 178.0K
- Earning Date
- CAPR 03-03-2025
- MEGI 01-01-0001
- Dividend Yield
- CAPR N/A
- MEGI 11.40%
- EPS Growth
- CAPR N/A
- MEGI N/A
- EPS
- CAPR N/A
- MEGI N/A
- Revenue
- CAPR $23,228,045.00
- MEGI N/A
- Revenue This Year
- CAPR N/A
- MEGI N/A
- Revenue Next Year
- CAPR $74.85
- MEGI N/A
- P/E Ratio
- CAPR N/A
- MEGI N/A
- Revenue Growth
- CAPR 65.33
- MEGI N/A
- 52 Week Low
- CAPR $3.52
- MEGI $10.63
- 52 Week High
- CAPR $23.40
- MEGI $14.89
- Technical
- Relative Strength Index (RSI)
- CAPR 52.56
- MEGI 54.45
- Support Level
- CAPR $14.28
- MEGI $12.50
- Resistance Level
- CAPR $16.47
- MEGI $12.67
- Average True Range (ATR)
- CAPR 1.00
- MEGI 0.16
- MACD
- CAPR 0.07
- MEGI 0.03
- Stochastic Oscillator
- CAPR 55.05
- MEGI 91.75
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
MainStay CBRE Global Infrastructure Megatrends Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It invests predominantly in income-producing equity securities issued by infrastructure companies, including common stock, preferred stock, convertible securities, and rights or warrants to buy common stocks. The company intends to focus on three infrastructure megatrends: decarbonization, digital transformation, and asset modernization while making its investments.